Add To Watchlist
Share URL
About The Company
CEO
Mr. Erik J. Deitsch
Market Cap
759.68 Thousand USD
Sector
Healthcare
Website
https://www.nutrapharma.comDescription
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States.
Read More
Overview
Value
26
Growth
73
Health
28
Management
42
Analyst Opinion
74
Total
49
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Has a low level of debt
- Price-to-earnings ratio of 0.1 is lower than the market average (19.6x)
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Earnings growth has slowed down recently
- Income is not covering expenditure and investment
- There is a history of diluting shareholders 0
- Does not hold enough liquid assets to cover short term liabilities
- Poor overall financial health
- No margin of safety at their current market price 0
Latest News

Nutra Pharma Provides Business and Compliance Updates
GlobeNewsWire | 16:30 Mon 26 Jul 2021
Read More →

Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures
GlobeNewsWire | 15:14 Fri 23 Jul 2021
Read More →

Nutra Pharma Engages Government Affairs Consulting Firm
GlobeNewsWire | 14:30 Thu 15 Jul 2021
Read More →

Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings
OTC PR Wire | 12:00 Tue 8 Jun 2021
Read More →
Market Peers
NPHC
Key Figures
PE Ratio (TTM)
0.13
Margin Of Safety (DCF)
-2206.91%
Revenue Growth (5 Year Average)
18.98%
Ratings Consensus
Buy
Share Buybacks
-7.16%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
26
- ✔ Price-to-earnings ratio of 0.1 is lower than the market average (19.6x)
- ✘ Estimated intrinsic-value of NaN undefined USD is lower than current price ( 100.00 undefined USD)
- ✘ Free-cashflow-yeild of -110.17% is worse than the market average (4.7%)
- ✘ Margin-of-safety of -2206.91% is worse than the market average (17.95%)
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 0 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
0.13x
Free Cashflow Yeild
-110.17%
PE/Earnings Growth
0.00
Price/Book
-0.06x
Growth
Growth Score
73
- ✔ 5 Year Average Revenue growth of 18.98% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 24.53% is higher than the market average (14.48%)
- ✔ 5 Year Average Cashflow growth of 15.98% is higher than the market average (12.35%)
- ✔ Free Cashflow growth has improved this year
- ✘ Earnings growth has slowed this year
Revenue Growth
18.98%
Earnings Growth
24.53%
Cashflow Growth
15.98%
Health
Health Score
28
Altman Z Score
N/A
Piostroski Score
6.00
Debt/Equity
N/Ax
Current Assets/Liabilities
0.03x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
18.16x
Management
Management Score
42
Average Buybacks/Dilution
-7.16%
Recent Buybacks/Dilution
0.06%
5 Year Price Volitility
N/A
Return On Assets
N/A
Return On Capital Employed
4.74%
Return On Equity
N/A
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
74
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Nutra Pharma Corp.
Currency
USD
Beta
0.471921
Vol Avg
667622
Ceo
Mr. Erik J. Deitsch
Cik
0001119643
Cusip
67060U208
Exchange
Other OTC
Full Time Employees
4
Industry
Drug Manufacturers—Specialty & Generic
Sector
Healthcare
Ipo Date
2013-01-02
Address
1537 NW 65th Avenue
City
Plantation
State
FL
Country
US
Zip
33313
Phone
954 509 0911
All financial data provided by FMP